1. Home
  2. INDP vs AXG Comparison

INDP vs AXG Comparison

Compare INDP & AXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

SELL

Current Price

$3.07

Market Cap

438.4M

Sector

Health Care

ML Signal

SELL

Logo Solowin Holdings Class A Ordinary Share

AXG

Solowin Holdings Class A Ordinary Share

HOLD

Current Price

$0.08

Market Cap

361.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDP
AXG
Founded
2000
2021
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
438.4M
361.1M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
INDP
AXG
Price
$3.07
$0.08
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
451.9K
★ 10.9M
Earning Date
11-11-2026
08-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$0.07
52 Week High
$5.96
$4.75

Technical Indicators

Market Signals
Indicator
INDP
AXG
Relative Strength Index (RSI) 55.54 11.61
Support Level $2.05 $0.07
Resistance Level $3.75 $2.46
Average True Range (ATR) 0.33 0.02
MACD 0.03 0.07
Stochastic Oscillator 78.48 11.72

Price Performance

Historical Comparison
INDP
AXG

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About AXG Solowin Holdings Class A Ordinary Share

Solowin Holdings Ltd is an investor-focused, versatile securities brokerage company in Hong Kong. It offers a wide spectrum of products and services through its secure one-stop electronic platform. It is engaged in providing securities-related services, investment advisory services, and asset management services to customers. The operations were organized into four reportable segments: Digital Asset Tokens, and AI Tokens. It generates maximum revenue from AI Tokens segment.

Share on Social Networks: